Life Sciences Consulting

Learn more

Life sciences companies face slower growth, rising development costs, and increasing pressure to demonstrate value beyond regulatory approval.

High-prevalence conditions are driving new blockbuster potential. Companies face tradeoffs between serving large populations and niche patient groups, with each path demanding different investments, access models, and go-to-market strategies.

At the same time, pricing pressure and evolving reimbursement models demand demonstrated real-world economic value to support adoption. Longer development timelines and lower success rates are pushing organizations to leverage data, analytics, and AI to improve discovery, accelerate development, and enhance commercialization.

~50% of future biopharma revenue growth

will come from external innovation such as M&A and licensing, effectively accelerating growth by shifting a substantial portion of value creation away from long-cycle internal R&D.

How Pharma Companies Are Driving the Next Wave of Revenue Growth

Meanwhile, an increasingly engaged ecosystem of patients, providers, and payers is driving demand for personalization, measurable outcomes, and transparency. Leading companies are moving beyond product portfolios toward platform-based models and more integrated, technology-enabled operating models.

Sciences companies turn to L.E.K. to develop and implement strategies that create sustainable, long-term value. We help clients navigate complex markets, identify growth opportunities, and prioritize investments for maximum impact. Our deep sector expertise spans prescription, consumer, primary care, specialty care, and other key markets.

L.E.K. works with clients to create practical strategies, guided by senior leadership, that enable informed decision-making. Our data-driven methods and flexible delivery model turn market insights into actionable plans. We help clients reduce development costs and accelerate timelines by aligning operations, technology, and commercialization with real-world value.

Value creation extends beyond organic growth, with M&A serving as a critical lever. Across every stage of the deal lifecycle, L.E.K. has supported life science clients in executing more than $140 billion in transactions, including in-licensing, out-licensing, strategic partnerships, M&A, joint ventures, divestitures, and royalty monetization.

AI at First Launch: Key Use Cases for Biotechs

Scaling from a development-stage biotech to a fully commercial organization is a pivotal moment in value creation, but it also brings greater operational complexity and financial risk. To manage this inflection point, emerging biotechs often adopt intentionally lean commercial models, including small field teams, tight budgets, limited customer-support capacity and fragmented data infrastructure.

Read more
The Biopharma Imperative

This collection brings together a focused selection of L.E.K. Consulting’s perspectives on the forces reshaping life sciences and biopharma. The sector continues to push at the boundaries of scientific possibility while navigating capital constraints, accelerating competition and rising expectations from patients, regulators and investors. The pieces included here examine those pressures with clarity and offer practical guidance on how leaders can respond with confidence.

Read more
From Discovery to Launch: Building Next-Generation Investment Governance for Biotech

This edition of L.E.K. Consulting’s Executive Insights offers a practical approach to framing investment trade-offs with concise actions to strengthen the operating model behind investment decisions.

Read more
In Pursuit of Prevalent Disease: Where the Next Mega-Blockbusters Will Be Built

Biopharma is entering a period during which the scale of its revenue base and the expectations placed on it by investors are fundamentally reshaping where the industry’s largest value pools will emerge.

Read more
The Race to Lead in Life Sciences Innovation: Lessons from Global Benchmarks

Global leaders like Boston, the Bay Area and the UK continue to set the pace, but rising hubs across Asia and the Middle East are quickly gaining ground. Our benchmark reveals how ecosystems succeed across funding, talent and commercialization — and what emerging markets must do to compete globally.

Read more